135 related articles for article (PubMed ID: 37877814)
1. Tarlatamab Shows Promise in SCLC.
Cancer Discov; 2023 Dec; 13(12):2494. PubMed ID: 37877814
[TBL] [Abstract][Full Text] [Related]
2. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Paz-Ares L; Champiat S; Lai WV; Izumi H; Govindan R; Boyer M; Hummel HD; Borghaei H; Johnson ML; Steeghs N; Blackhall F; Dowlati A; Reguart N; Yoshida T; He K; Gadgeel SM; Felip E; Zhang Y; Pati A; Minocha M; Mukherjee S; Goldrick A; Nagorsen D; Hashemi Sadraei N; Owonikoko TK
J Clin Oncol; 2023 Jun; 41(16):2893-2903. PubMed ID: 36689692
[TBL] [Abstract][Full Text] [Related]
3. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
[TBL] [Abstract][Full Text] [Related]
4. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
Ahn MJ; Cho BC; Felip E; Korantzis I; Ohashi K; Majem M; Juan-Vidal O; Handzhiev S; Izumi H; Lee JS; Dziadziuszko R; Wolf J; Blackhall F; Reck M; Bustamante Alvarez J; Hummel HD; Dingemans AC; Sands J; Akamatsu H; Owonikoko TK; Ramalingam SS; Borghaei H; Johnson ML; Huang S; Mukherjee S; Minocha M; Jiang T; Martinez P; Anderson ES; Paz-Ares L;
N Engl J Med; 2023 Nov; 389(22):2063-2075. PubMed ID: 37861218
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
[TBL] [Abstract][Full Text] [Related]
6. DLL3: an emerging target in small cell lung cancer.
Owen DH; Giffin MJ; Bailis JM; Smit MD; Carbone DP; He K
J Hematol Oncol; 2019 Jun; 12(1):61. PubMed ID: 31215500
[TBL] [Abstract][Full Text] [Related]
7. Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
Mak DWS; Li S; Minchom A
Eur J Cancer; 2019 Sep; 119():132-150. PubMed ID: 31445197
[TBL] [Abstract][Full Text] [Related]
8. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
[TBL] [Abstract][Full Text] [Related]
9. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
Meder L; Schuldt P; Thelen M; Schmitt A; Dietlein F; Klein S; Borchmann S; Wennhold K; Vlasic I; Oberbeck S; Riedel R; Florin A; Golfmann K; Schlößer HA; Odenthal M; Buettner R; Wolf J; Hallek M; Herling M; von Bergwelt-Baildon M; Reinhardt HC; Ullrich RT
Cancer Res; 2018 Aug; 78(15):4270-4281. PubMed ID: 29776963
[TBL] [Abstract][Full Text] [Related]
10. Unravelling the biology of SCLC: implications for therapy.
Sabari JK; Lok BH; Laird JH; Poirier JT; Rudin CM
Nat Rev Clin Oncol; 2017 Sep; 14(9):549-561. PubMed ID: 28534531
[TBL] [Abstract][Full Text] [Related]
11. Overcoming chemoresistance of small-cell lung cancer through stepwise HER2-targeted antibody-dependent cell-mediated cytotoxicity and VEGF-targeted antiangiogenesis.
Minami T; Kijima T; Kohmo S; Arase H; Otani Y; Nagatomo I; Takahashi R; Miyake K; Higashiguchi M; Morimura O; Ihara S; Tsujino K; Hirata H; Inoue K; Takeda Y; Kida H; Tachibana I; Kumanogoh A
Sci Rep; 2013; 3():2669. PubMed ID: 24036898
[TBL] [Abstract][Full Text] [Related]
12. Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody-Drug Conjugate.
Lashari BH; Vallatharasu Y; Kolandra L; Hamid M; Uprety D
Drugs R D; 2018 Dec; 18(4):255-258. PubMed ID: 30232719
[TBL] [Abstract][Full Text] [Related]
13. The prognostic implications of Notch1, Hes1, Ascl1, and DLL3 protein expression in SCLC patients receiving platinum-based chemotherapy.
Tendler S; Kanter L; Lewensohn R; Ortiz-Villalón C; Viktorsson K; De Petris L
PLoS One; 2020; 15(10):e0240973. PubMed ID: 33104707
[TBL] [Abstract][Full Text] [Related]
14. Targeting hypoxia in the treatment of small cell lung cancer.
Bryant JL; Meredith SL; Williams KJ; White A
Lung Cancer; 2014 Nov; 86(2):126-32. PubMed ID: 25201720
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models.
Sun D; Nikonova AS; Zhang P; Deneka AY; Fitzgerald ME; Michael RE; Lee L; Lilly AC; Fisher SL; Phillips AJ; Nasveschuk CG; Proia DA; Tu Z; Golemis EA
Mol Cancer Ther; 2021 Aug; 20(8):1367-1377. PubMed ID: 34045230
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain and hedgehog pathway targets in small cell lung cancer.
Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
[TBL] [Abstract][Full Text] [Related]
17. Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.
Polley E; Kunkel M; Evans D; Silvers T; Delosh R; Laudeman J; Ogle C; Reinhart R; Selby M; Connelly J; Harris E; Fer N; Sonkin D; Kaur G; Monks A; Malik S; Morris J; Teicher BA
J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27247353
[TBL] [Abstract][Full Text] [Related]
18. EphA2 inhibition suppresses proliferation of small-cell lung cancer cells through inducing cell cycle arrest.
Ishigaki H; Minami T; Morimura O; Kitai H; Horio D; Koda Y; Fujimoto E; Negi Y; Nakajima Y; Niki M; Kanemura S; Shibata E; Mikami K; Takahashi R; Yokoi T; Kuribayashi K; Kijima T
Biochem Biophys Res Commun; 2019 Nov; 519(4):846-853. PubMed ID: 31558317
[TBL] [Abstract][Full Text] [Related]
19. Advances in pharmacotherapy of small cell lung cancer.
Kalemkerian GP
Expert Opin Pharmacother; 2014 Nov; 15(16):2385-96. PubMed ID: 25255939
[TBL] [Abstract][Full Text] [Related]
20. Targeting gastrin-releasing peptide receptors on small cell lung cancer cells with a bispecific molecule that activates polyclonal T lymphocytes.
Zhou J; Chen J; Zhong R; Mokotoff M; Shultz LD; Ball ED
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2224-31. PubMed ID: 16609038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
